# NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH

## NATIONAL CANCER REGISTRY PROGRAMME

Indian Council of Medical Research

## PATTERNS OF CARE AND SURVIVAL STUDIES

Patient Information Form - Cancer Cervix

Α.	IDEN	ITIFYING, DEMOGRAPHIC AND DIAGNOSTIC INFORMATION							
1.	Nam	e of Participating Centre		. Cer	ntre C	ode			
2.		stration Number (as in HBCR) 2 digits are for year of registration and the next 5 digits for actual registration number)							
	•			ear			Reg. I	Vo.	
3.1	(a)	Name of Source of Registration			C	ode			
	(b)	Name of Department / Unit etc.			C	ode			
	(c)	Name of Physician Mobile No.							
3.2	Hosp	oital Registration Number							
0.0	Data	of Designation of Course of Designation /			_				
3.3		of Registration at Source of Registration / of Reporting at this Hospital			L				
3.4	Case	e Registered As				dd	mn	1	уу
	(1) O	ut-patient (OP) (2) In-patient (IP)							
	(3) O	P and IP (4) Not Registered	- Clinic	al Con	sultati	on / Op	oinion		
	(5) No	ot Registered - Pathology Consultation / Opinion (8) Others (specify).							
4.		of First Diagnosis							
	(Date	of first attendance to any hospital for this disease)			L	dd	l mn	<u></u> า	уу
5.		Name of Patient Second					 Last		
6.	Nam	e of Spouse / Father / Mother / Caretaker (give any two names)							
0.									
		Name Mobile No. Name				М	obile No.	• • • • • • • • • • • • • • • • • • • •	
7.	Place	e of Residence: Permanent place of residence (where the person has been residence)	ing for	the pa	st one	year (a	at least	<del>'</del> )))	
	<u>Urba</u>	An Areas (Town / city / any other)	ural A	reas					
	Hous	se No House No. and	House No. and Ward						
	Road	d / Street Name		•					
	Area	(1) 196	Name of Sub-Unit of District (Taluk / Tehsil / Other):						
	Ward	d / Corporation / Division							
	Nam	e of City / Town	Sub	Centr	е				
	Nam	e of District (in capitals)	tal Pi	n Coo	de 🗌				
	Telep	phone No(s).: Off Res							
	Mobi	ile No Email ID							
	Aadh	naar (Unique Identification) No.							

8.	Duration of Stay (at the permanent place of residence (in years))							
9.1	Local Address	9.2 Name & Add	ress	of Refer	ring /	Family D	Octo	or
10. 11.	Name of City/Town/District  Pin Code  Age (in years)  Sex - Female	Name of City/Tow Pin Code Date of Birth		etrict				
12.	Method of Diagnosis  (1) Clinical Only (2) Microscopic (8) Others (9) Unknown	(3) X-Ray / Imagi	ng Tec	hniques				
	Microscopic (if 2 above)  (1) Histology of Primary  (2) Histology of Metastasis  (3) Cytology of Primary  (4) Cytology of Metastasis  (5) Angiography  (6) All Others (specify)	(1) S (2) S (3) C (8) C	urgery pecific	Biochem unologica	ical and I Tests	out Histolog		
13.	Anatomical Site of Specimen / Biopsy / Smear							
14.	Complete Pathological Diagnosis: (With complete description of Primary Site of Tumour and Morphological Diagnosis)							
14.1	Primary Site of Tumour - Topography							
14.2	Morphology							
14.3	Pathology Slide No.	Date						
15.	Coding According to ICD-O-3:	L	dd	mm	уу	_		
15.1	Primary Site of Tumour - Topography(Include sub-site if any)			С				
15.2	Primary Histology - Morphology		М					
15.3	If morphology is that of metastasis mention Primary Site above and  Secondary Site of Tumour							
15.4	Morphology of Metastasis		м				<del> </del>	ᆜ
10.4	If the morphology diagnosis is only that of metastatic site, mention the as decided by the treating clinician either through discussion or from a	Primary Site	··· L			/		
16.	Sequence							
	(0) One Primary Only (1) First of two or mo	ore primaries	(2)	Second of	two or n	nore primar	ies	
	(3) Third of three or more primaries (4) Fourth of four or r	more primaries	(5)	Fifth of five	or more	e primaries		
	(6) Sixth of six or more primaries (7) Seventh of seven	or more primaries	(8)	Eighth or la	ater prim	nary		
	(9) Unspecified sequence number (Unknown)							

Co-Morbid Conditions (1) Tuberculosis (3) Diabetes (5) Bronchial Asthma (7) Hepatitis / HBsAg +ve (10) AIDS/HIV +ve	Yes No Unknown	Co-Morbid Conditions  (2) Hypertension  (4) Ischaemic Heart Disease  (6) Allergic Conditions (specify)	
DETAILS OF STAGE (Tick (	√) as appropriate)		
Staging System Followed (1) FIGO staging	(2) TNM staging	(8) Others (specify)	(9) Unknown
Staging done at (1) Reporting Institution	(2) Previous Institution	on (8) Others (specify)	(9) Unknown
Stage	IA1 [ IB1 [ IIA1 [ IIIB [ IIVB [	IA2	IIB
If TNM specify	Т	N M	
Investigations for Staging  (1) Haemogram  (3) Chest X-ray  (5) Cystoscopy  (7) Proctosigmoidoscopy  (10) CT Scan	Yes No Unknown	<ul><li>(2) Biochemistry</li><li>(4) Examination under Anaesthesia</li><li>(6) Ultrasound of abdomen &amp; pelvis</li><li>(8) Others (specify)</li></ul>	Yes No Unkno
Specify any relevant abnor	mal findings		
The actual assessment of (1) One Consultant Oncolog	<u> </u>	] (2) Two COs from same dep	partment

D.	<b>DETAILS OF CANCER DIRECTED TREATMENT (CDT)</b> (Tick (✓) as appropriate)					
6.	Trea	tment given prior to Registration at Reporting Institution (RI)				
	(0)	No (2) Yes (9) Unknown				
	If yes	5,				
6.1	Type	of Prior Treatment Given:  Yes  No  Unknown  If yes, Date of completion of treatment				
	(1)	Surgery				
	(2)	Radiotherapy				
	(3)	Chemotherapy				
	(8)	Others (specify)				
		dd mm yy				
6.2	Deta	ils of Prior Treatment (including treatment interruption and complications)				
7.	Trea	tment at Reporting Institution				
7.1	Inten	ition to Treat				
	(1)	Curative/Radical (2) Palliative				
	(3)	No treatment (9) Unknown				
7.2	If Pa	lliative yes,				
	(1)	Palliative RT only (2) Palliative RT + CT (3) Palliative CT only				
	(4)	Pain & Symptom Relief Drugs (specify)				
	(8)	Others (specify)				
7.0	_					
7.3	Туре	of Cancer Directed Treatment Planned at Reporting Institution:  Yes No Unknown				
	(1)	Surgery				
	(2)	Radiotherapy				
	(3)	Chemotherapy				
	(8)	Others (specify)				
8.	Perf	ormance Status (WHO) before treatment				
	(0)	Able to carry out all normal activity without restriction				
	(1)	Restricted in physically strenuous activity but ambulatory and able to carry out light work				
	(2)	Ambulatory and capable of all self-care but unable to carry out any work; up and about more than 50% of waking hours				
	(3)	Capable of only limited self-care; confined to bed or chair more than 50% of waking hours				
	(4)	Completely disabled; cannot carry on any self-care; totally confined to bed or chair				
	(9)	Unknown				

9.	Surg	jery									
9.1	(0)	Surgery not planne	ed	[		(1)	Yes, d	lone a	as planned/adv	rised	
	(2)	Surgery planned b	ut not take	en [		(8)	Others	S (spe	cify)		
	(9)	Unknown		[							
9. 2	If yes	s, Type of Surgical	Procedure	Э							
	(1)	Total (extra-fascial	) Abdomina	al Hys	sterectomy (Type I)		(	5) P	elvic Excentera	ation	
	(2)	Modified Radical H	Hysterector	ny (Ty	/pe II)		(	8) O	thers (specify)		
	(3)	Radical Abdomina	l Hysterect	omy (	(Type III)		(	9) U	nknown		
	(4)	Extended Radical	Hysterecto	my (1	Type IV)						
9.3	If yes	s, Lymphadenecto	y	(1	) Not Done	(2)	Done				
9.4	Date	of Surgical Proce	dure		dd mm	уу					
10.	Surgical Histopathological Findings										
40.4	0:	- ( T									
10.1		of Tumour in Cerv	∕IX □	(4)	No Viable turas		(2)	T		- NUZ\	
	(0)	NA*		(1)	No Viable tumor				or present (Size	e NK)	
	(3)	Tumor < 2 cm		(4)	Tumor 2-4 cm NK**		(5)	rumo	or 4 - 6 cm		
	(6)	Tumor > 6 cm		(9)	INK						
10.2	Thick	kness of Cervical I	nvasion								
	(0)	NA		(1)	< 1/3 / in-situ			(2)	< 1/2		
	(3)	= 2/3		(4)	Full thickness			(9)	NK		
10.3	Invol	vement of Uterus									
	(0)	NA		(1)	Not involved						
	(2)	Involved		(3)	Endocervix extn.			(9)	NK		
10.4	Thick	kness of Uterine Ir	ıvasion								
	(0)	NA		(1)	Endometrium			(2)	Myometrium		
	(3)	Serosa + ve		(9)	NK			\-/	.,		
	(-/			(-)							

<sup>\*</sup> Not Applicable, \*\* Not Known

10.5	.5 Involvement of Vagina (Cut edges)							
	(0) NA []	) Negative		(2) Positive				
	(3) Edge Close / +ve (9)	) NK						
10.6	Involvement of Parametrium							
	(0) NA (1) Negative		(2) Posit	ive 🗌	(9) NK			
40 -								
10.7	Tumor Emboli							
	(0) NA (1) No		(2) Yes		(9) NK			
10.8	Involvement of Ovaries							
	(0) NA (1) Not invol	ved $\square$	(2) Involved		(9) NK			
			(_,					
10.9	10.9 Involvement of Regional Nodes							
	(0) NA (1) Not invol	ved	(2) Involved	l (Metastatic) 🗌	(9) NK			
10.10 Site of Involved Regional Nodes								
	(0) NA (1) No	ot involved		(2) Ilio- obtur.				
	(3) Iliac node (4) Ol	oturator		(5) Pre- Sacra	al 🗌			
	(6) Paracervical (7) Pa	arametrial		(9) NK				
40.44								
10.11	Para-aortic Node(s)	1						
	(0) NA (1) Not involved	] (2) In	volved (Metasta	tic) [] (9	9) NK 📙			
10.12	2 Laterality of Positive Nodes							
	(0) NA	) Not involved	ı 🗆					
	(2) Unilateral ( R / L) (3	) Bilateral		(9) NK	7			
		,		` ,	_			
10.13	No. of Positive Nodes							
	0	3 🗌	4	>4	NK 🗌			
10.14	Tumour Grade							
	(0) NA (1) Gr	ade I		(2) Grade II				
	(3) Grade III (4) Gr	ade IV		(9) NK				
10.45	Chambana and a Carara la chambana							
10.15	5 Lymphovascular Space Involvement	(0)		(O) NII -	٦			
	(0) NA (1) Not involved	(2) Inv	roivea 🔲	(9) NK				

11.	Radiotherapy						
11.1	(0) Radiotherapy (RT) not plan	nned 🗌	(1) Ye	s, RT given as	planned		
	(2) Yes, RT given, but incomple (specify reason)			planned but no	ot taken		
	(8) Others (specify)		(9) Un	known			
11.2	Type of RT						
	(1) Teletherapy (External RT)	<u>(2)</u>	Brachytherapy	<u>(3)</u>	3D Conformal		
	(4) IMRT	<u>(5)</u>	Electron Beam				
	(8) Others (specify)			<u>(9)</u>	Unknown		
11.3	Details of External RT	I		II	III		
	Technique (specify)						
	Type of beam (Photon/Electron)						
	Energy						
	Field Size						
	Field/day						
	Total Tumour Dose (cGy)						
	Total No. of Fractions						
	Fractions / week						
	Region(s) of Irradiation						
	Interruption - YES (Y) / NO (N)						
	Date first started						
	Date last ended dd	mm yy	dd mm	уу	dd mm	уу	


11.4	Detai	Is of Brachytherap	У									
		1	II		III		IV		V		>\	
	Date	dd mm yy	dd mm	yy dd	mm	yy dd	mm yy	dd	mm yy	dd	mm	УУ
	Туре	of applicators										
		of Dose Rate MDR/HDR/PDR)										
	Dose	rate in cGy.										
	Dose in cG	to Rectum y.										
	Dose in cG	to Bladder y.										
12.	Chen	notherapy										
12.1	(0)	Chemotherapy (C	CT) not planned	d [		(1)	Yes, CT gi	ven as	planned			
	(2)	Yes, CT given, bu	ut incomplete			(3)	CT planne	d but r	not taken			
	(8)	Others (specify)				(9)	Unknown					
	If Yes	<b>5</b> ,										
12.2	Туре	of CT										
	(1)	Anterior/neo-adju	vant/induction			(2)	Concurren	it				
	(3)	Adjuvant				(4)	Combinati	on of a	ny of the ab	ove		
	(8)	Others (specify)		[		(9)	Unknown					
12.3	Drug(	(s) comprising CT	Regimen									
	(1)	Single (specify)				(2)	Two Drug	(specify)				
	(3)	More than two dro	ug (specify)			(8)	Others (spe	ecify)				
	(9)	Unknown										

#### 12.4 Other Details of CT

Height in cms			Weigh	t in Kg.			
Cycles	1	II	III	IV	V	VI	>VI
Regimen							
Date(s)	dd mm yy	dd mm yy	dd mm y				
Day(s)							
Drug (s)							
Name	Dose	Dose	Dose	Dose	Dose	Dose	Dose
Date of start of First Cycle of		mm yy			completion of cle of CT	dd mm	уу

### 13. Response of Disease (Adopted from WHO) to RT / RT + CT (6-12 weeks after completion of treatment)

- (9) Unknown
- 13.1 Date(s) of assessment of response to RT / RT + CT



dd	mm	уу

#### 14.1 Date of Completion of Initial Cancer Directed Treatment at RI

#### 14.2 Complications During Treatment

(0)	No 🗌	(2) Yes	(9) Unknown
-----	------	---------	-------------


If Yes.

Nature of Complication(s)	Maximum Grade	Date of Onset	Resolved Yes No	Date last seen ( if resolved)
		dd mm vv		dd mm yy

### 15. Performance Status at 6-12 Weeks of Completion of all of CDT

- (0) Able to carry out all normal activity without restriction
- (1) Restricted in physically strenuous activity but ambulatory and able to carry out light work
- (2) Ambulatory and capable of all self-care but unable to carry out any work; up and about more than 50% of waking hours
- (3) Capable of only limited self-care; confined to bed or chair more than 50% of waking hours
- (4) Completely disabled; cannot carry on any self-care; totally confined to bed or chair
- (9) Unknown

#### 15.1 Date of Assessment of Performance Status



E.	FOLLOW-UP INFORMATION (USE SEPA	ARATE PAGE FOR EACH VISIT)		
16.	Due Date for Follow up	Date of Actual Follow-up	Follow-up \	/isit No.
16.1	dd mm yy  Method of Follow-up	dd mm yy		
10.1		(1) Hospital visit	(2) By post	Г
		(4) Home visit	(2) By post	L
	(3) Through telephone (	(4) Home visit	(8) Others (specify)	[
40.0	V(1) 1 (1) 1		(9) Unknown	L
16.2	Vital Status	(0) 11 1		
	(1) Alive (2) Dead	(9) Unknown		
16.3	Disease Status (at Follow-up)			
	(1) No Evidence of Disease		(2) Residual Disease only	
	(3) Local recurrence		(4) Regional/Nodal recurrence	
	(5) Distant metastasis : specify site		(9) Unknown	
16.4	If Disease is present, indicate Basis of D	Diagnosis		
10.4		Cytopathology	(3) FNAC	
		(Other than FNAC)		
	(4) Bone Marrow (5) F	Peripheral Smear	(6) Radiological	
	(7) Clinical (8) (	Others (specify)	[] (9) Unknown	
16.5	Treatment if 16.3 above indicates prese	nce of disease		
10.5		∕es, Treatment given Γ	(9) Unknown	
	(b) No Treatment (2) 1	co, rreatment given		
16.6	If yes, Details of Treatment and Outcom	e (Use separate sheet if necessar	ry)	
16.7	Late Complications of CDT			
	(0) Nil (2) Yes (9) U	nknown		
	If Yes,			
	Nature of Complication(s) Maximum	Grade Date of Onset		
			Yes No (if resolu	/ed)
		dd mm yy	y dd mm	

17.	Second Primary  (0) No evidence of second primary (2) Yes, evidence of second primary	ary 🗌 (9) Unknown 📗					
	If Yes,						
17.1	Primary Site of Tumour (ICD-O-3) (Topography)	C .					
17.2	Primary Histology (ICD-O-3) (Morphology)	м					
17.3	Secondary (Metastatic) Site of Tumour (ICD-O-3)	с .					
17.4	Histology of Metastasis	м/					
17.5	Method of Diagnosis  (1) Clinical Only (2) Microscopic (3) X-Ray / Imaging Techniques (8)	3) Others					
17.6	(1) Histology of Primary (1) X-Ray (1) End. (2) Histology of Metastasis (2) Isotopes (2) Surg. (3) Autopsy with Histology (3) Angiography (3) Spec. (4) Bone Marrow (4) Ultrasonogram or Ir	oscopy gery or Autopsy without Histology cific Biochemical and / mmunological Tests gers (specify)					
	dd mm yy						
17.7 <b>18.</b>	Details of Treatment and Outcome: Use separate appropriate form.  If Dead,						
18.1	Cause of Death  (1) As a result of cancer	(3) Intercurrent Death (9) Unknown					
18.2	Date of Death						
19.	9. Remarks (add additional sheet(s) if necessary)						